Last reviewed · How we verify
tiotropium bromide inhalation powder HandiHaler
Tiotropium is a long-acting anticholinergic (antimuscarinic) agent that blocks muscarinic M3 receptors on airway smooth muscle to produce sustained bronchodilation.
Tiotropium is a long-acting anticholinergic (antimuscarinic) agent that blocks muscarinic M3 receptors on airway smooth muscle to produce sustained bronchodilation. Used for Chronic obstructive pulmonary disease (COPD) maintenance treatment, Asthma maintenance treatment.
At a glance
| Generic name | tiotropium bromide inhalation powder HandiHaler |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Long-acting muscarinic antagonist (LAMA) |
| Target | Muscarinic M3 receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | FDA-approved |
Mechanism of action
Tiotropium binds to muscarinic M3 receptors on airway smooth muscle cells, preventing acetylcholine-induced bronchoconstriction. This results in sustained airway relaxation and improved airflow. The drug is formulated as an inhalation powder for direct delivery to the lungs, providing once-daily, 24-hour bronchodilatory effect in chronic obstructive pulmonary disease (COPD) and asthma.
Approved indications
- Chronic obstructive pulmonary disease (COPD) maintenance treatment
- Asthma maintenance treatment
Common side effects
- Dry mouth
- Tremor
- Headache
- Pharyngitis
- Urinary retention
Key clinical trials
- Efficacy and Safety of Indacaterol vs Tiotropium in Women With COPD Secondary to Biomass Exposure (PHASE4)
- Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Respimat Device in Patients With Chronic Obstructive Pulmonary Disease (COPD) (PHASE2)
- Phase 4 COPD and Suboptimal Inspiratory Flow Rate (PHASE4)
- A Trial to Assess the Bioequivalence of Tiotropium Bromide Inhalation Powder in Healthy Adult Participants Under Fasting Conditions (PHASE1)
- A Trial to Assess the Bioequivalence of Generic Tiotropium Bromide Inhalation Powder and Reference Product in Healthy Adult Participants Under Fasting Conditions (Pilot) (PHASE1)
- Bioequivalence Study of Tiotropium 18 μg Inhalation Powder, Hard Capsule With Spiriva®Handihaler® 18 μg Inhalation Powder, Hard Capsule in Patients With Chronic Obstructive Pulmonary Disease (COPD) (PHASE3)
- Efficacy and Safety Comparison of Tiotropium Inhalation Solution (Respimat Inhaler) and Spiriva HandiHaler in COPD (PHASE3)
- Pharmacokinetics and Safety Comparison of Tiotropium Inhalation Powder Administered as the Bromide Salt From Hard Polyethylene Capsule Via the HandiHaler® 2 and Spiriva® HandiHaler® in Patients With Chronic Obstructive Pulmonary Disease (COPD) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: